- Home
- ROIV
as 12-20-2024 4:00pm EST
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
| Founded: | 2014 | Country: | United Kingdom |
| Employees: | N/A | City: | HAMILTON HM11 |
| Market Cap: | 8.8B | IPO Year: | N/A |
| Target Price: | $17.93 | AVG Volume (30 days): | 5.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 5.89 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.69 - $13.06 | Next Earning Date: | 02-11-2025 |
| Revenue: | $129,128,999 | Revenue Growth: | 145.68% |
| Revenue Growth (this year): | 15.98% | Revenue Growth (next year): | -29.49% |
Stock Insider Trading Activity of Roivant Sciences Ltd. (ROIV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Venker Eric | ROIV | President & COO | Nov 20 '24 | Sell | $11.32 | 100,000 | $1,132,000.00 | 606,525 | |
| Venker Eric | ROIV | President & COO | Oct 20 '24 | Sell | $11.65 | 100,000 | $1,165,000.00 | 606,525 | |
| QVT Financial LP | ROIV | N/A | Sep 25 '24 | Sell | $11.80 | 926,000 | $10,942,820.00 | 23,055,358 | |
| Gold Daniel Allen | ROIV | Director | Sep 24 '24 | Sell | $11.73 | 4,426,000 | $51,820,727.30 | 4,731,830 | |
| MANCHESTER KEITH S | ROIV | Director | Sep 24 '24 | Sell | $11.70 | 503,000 | $5,866,308.20 | 1,412,126 |
Latest Roivant Sciences Ltd. News
ROIV Breaking Stock News: Dive into ROIV Ticker-Specific Updates for Smart Investing
GlobeNewswire
19 days ago
Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
GlobeNewswire
19 days ago
Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
Simply Wall St.
a month ago
Roivant Sciences' (NASDAQ:ROIV) Shareholders Should Assess Earnings With Caution
GlobeNewswire
a month ago
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update
GuruFocus.com
a month ago
Roivant Sciences Ltd (ROIV) Q2 2025 Earnings Report Preview: What To Expect
GlobeNewswire
2 months ago
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
GlobeNewswire
2 months ago
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
Argus Research
3 months ago
Daily – Vickers Top Buyers & Sellers for 09/27/2024
Compare ROIV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ROIV Roivant Sciences Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.